"paper"

Our Paper of the Month for October 2023 is a multicentre, prospective, randomised clinical trial investigating whether transdermal nicotine may have a disease-modifying effect in early, therapy-naïve Parkinson's disease.

Our paper of the month presents the results of a randomised trial assessing AXER-204, a soluble decoy fragment of NgR1 able to block the action of three inhibitors of the axonal growth in individuals with chronic traumatic cervical SCI.

Our paper of the month is a phase 3, double-blind, multicentre, trial investigating the efficacy and the safety of vorasidenib, a dual inhibitor of the IDH1 and IHD2 enzymes, in patients with residual or recurrent IDH mutant grade 2 gliomas.

This month we have selected two papers of the month, reporting the results of two randomised, double-blind, placebo-controlled, phase III trials investigating potential therapies for generalised Myasthenia Gravis.

Co-Chair of the EAN Scientific Panel on Dementia and Cognitive Disorders answers three key questions about a groundbreaking Alzheimer study.

Our paper of the month is a phase 1b, randomised, multicentre, placebo-controlled trial, which aims to investigate the safety, pharmacokinetics, and effects of MAPTRx in patients with mild Alzheimer's.

Our April paper of the month investigates the association between focal epilepsy and risk of incident dementia compared with patients with stroke or migraine and with healthy controls.

On the occasion of the Brain Awareness Week, the European Brain Council and the European Federation of Pharmaceutical Industries and Associations have launched the RETHINKING Alzheimer’s disease White Paper.

Our paper of the month presents the results of a prospective, double-blind, randomised, sham-controlled trial involving 16 centres and investigating the safety and efficacy of unilateral FUSA of the globus pallidus internus in patients with medication-refractory idiopathic PD.

Our February Paper of the Month is a narrative review focusing on epidemiology, pathophysiology and treatment of secondary headache following SARS-COV-2 infection and vaccination, and on the impact of COVID-19 pandemic on primary headache disorders.

Our paper of the month is a retrospective nationwide cohort study that was carried out to determine the clinical sequelae of long covid for a year after infection in patients with mild disease, and to evaluate its association with age, sex, SARS-CoV-2 variants, and vaccination status.

Our paper of the month reports the results of the ENCHANTED 2/MT trial, performed in 44 Chinese hospitals to compare more intensive with less intensive blood pressure management after successful endovascular thrombectomy.

Our authors of the month compared the occurrence of stroke, utilisation of recanalisation procedures, and demographic parameters during the pandemic period with data from the preceding year.

Registration is now open for the launch event of the RETHINKING Alzheimer’s disease White Paper, taking place virtually on 24 January 2023 at 12:30 – 14:00.

Our authors of the month report the results of a multicentre phase-3 clinical trial exploring efficacy and safety of Lecanemab in patients with early AD over a follow-up period of eighteen months.